Massively distended, necrotic and hemorrhagic gallbladder in a long-term octreotide-treated patient with added everolimus.
Carcinoid cancer
Cholecystitis
Cholelithiasis
Everolimus
Octreotide
Journal
International journal of surgery case reports
ISSN: 2210-2612
Titre abrégé: Int J Surg Case Rep
Pays: Netherlands
ID NLM: 101529872
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
05
2019
accepted:
11
07
2019
pubmed:
29
7
2019
medline:
29
7
2019
entrez:
29
7
2019
Statut:
ppublish
Résumé
Long-term treatment with somatostatin analogs, such as octreotide, is well known to promote gallstones formation. Immunosuppressive therapy in renal transplantation is also associated with increased occurrence of gallstones. But acute cholecystitis develops only in a few cholelithiasis patients. However, it is not known whether long-term somatostatin analog therapy and immunosuppressants aggravate the severity of disease if the patient develops cholecystitis. We present a case of severe cholecystitis in a patient with metastatic carcinoid cancer on octreotide long-acting release therapy for seven years with newly added immunosuppressant, everolimus. Cholelithiasis as well as cholecystitis develop more often in patients on somatostatin analogs and immunosuppressants than in general population. However, morbidity remains negligible. No conclusion can be drawn on the contribution of somatostatin analogs and immunosuppressant in the occurrence of severe cholecystitis. Prophylactic cholecystectomy is not indicated in patients with this medication.
Identifiants
pubmed: 31352317
pii: S2210-2612(19)30396-7
doi: 10.1016/j.ijscr.2019.07.014
pmc: PMC6664011
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107-110Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Best Pract Res Clin Gastroenterol. 2006;20(6):981-96
pubmed: 17127183
BMJ. 2007 Aug 11;335(7614):295-9
pubmed: 17690370
J Endocrinol Invest. 2008 Aug;31(8):704-10
pubmed: 18852531
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
World J Surg. 2010 Jun;34(6):1361-7
pubmed: 20130865
J Oncol Pharm Pract. 2011 Sep;17(3):274-8
pubmed: 20215482
Ann Surg Oncol. 2014 Jan;21(1):240-7
pubmed: 24114054
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Expert Opin Drug Saf. 2015 Aug;14(8):1213-26
pubmed: 26184380
J Hepatol. 2016 Jul;65(1):146-181
pubmed: 27085810
Ther Clin Risk Manag. 2017 Oct 13;13:1391-1398
pubmed: 29075123
Dig Liver Dis. 2019 May;51(5):689-694
pubmed: 30314949
Int J Surg. 2018 Dec;60:132-136
pubmed: 30342279
Hepatology. 1995 Mar;21(3):655-60
pubmed: 7875663
Clin Endocrinol (Oxf). 1994 Mar;40(3):401-6
pubmed: 8187305
Cancer. 1997 Feb 15;79(4):830-4
pubmed: 9024721